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Abstract
Mutations in the ABCC6 ABC-transporter are causative of pseudoxanthoma elasticum (PXE). The loss of functional ABCC6
protein in the basolateral membrane of the kidney and liver is putatively associated with altered secretion of a circulatory
factor. As a result, systemic changes in elastic tissues are caused by progressive mineralization and degradation of elastic
fibers. Premature arteriosclerosis, loss of skin and vascular tone, and a progressive loss of vision result from this ectopic
mineralization. However, the identity of the circulatory factor and the specific role of ABCC6 in disease pathophysiology are
not known. Though recessive loss-of-function alleles are associated with alterations in ABCC6 expression and function, the
molecular pathologies associated with the majority of PXE-causing mutations are also not known. Sequence analysis of
orthologous ABCC6 proteins indicates the C-terminal sequences are highly conserved and share high similarity to the PDZ
sequences found in other ABCC subfamily members. Genetic testing of PXE patients suggests that at least one disease-
causing mutation is located in a PDZ-like sequence at the extreme C-terminus of the ABCC6 protein. To evaluate the role of
this C-terminal sequence in the biosynthesis and trafficking of ABCC6, a series of mutations were utilized to probe changes
in ABCC6 biosynthesis, membrane stability and turnover. Removal of this PDZ-like sequence resulted in decreased steady-
state ABCC6 levels, decreased cell surface expression and stability, and mislocalization of the ABCC6 protein in polarized
cells. These data suggest that the conserved, PDZ-like sequence promotes the proper biosynthesis and trafficking of the
ABCC6 protein.
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Introduction
Pseudoxanthoma elasticum (PXE) is a disease characterized by
the progressive mineralization of elastic fibers. [1,2] The
mineralization and eventual degradation of these fibers cause a
loss of elasticity in a variety of affected tissues. While the molecular
mechanisms leading to the mineralization processes are unknown,
mutations in the ABCC6 ATP-binding cassette (ABC-) transporter
have been shown to be causative of the disease. [3,4] To date,
more than 250 coding and noncoding mutations have been
identified in ABCC6 that are associated with PXE. [5–7] The
resulting loss of protein function in the basolateral membrane
putatively alters the secretion of one or more unknown circulatory
factors that systemically affect the mineralization of elastic fibers.
[8] This mineralization and subsequent degradation of elastic
fibers lead to loss of vascular tone, premature arteriosclerosis,
laxity in the skin, and loss of vision, resulting from neovascular-
iziation in the eye. [2].
The ABC-transporter family of proteins is responsible for the
secretion of a variety of biological molecules across the cell
membrane in an ATP dependent manner. [9] Structurally, the
proteins are composed of at least four core domains: two
transmembrane domains (TMDs) and two nucleotide-binding
domains (NBDs). ATP binding between the NBDs induces their
dimerization, which, in turn leads to ATP hydrolysis. [10–12]
These ATP-induced conformational changes are coupled through
a conserved interface to the TMDs, which utilize the energy of
ATP binding and hydrolysis to facilitate solute transport. [13,14]
In addition, the long form ABCC subfamily members, including
ABCC6, contain an additional N-terminal transmembrane
domain whose function is not well defined. [9] Alterations in
protein biosynthesis, protein trafficking and localization, ATP
binding and hydrolysis, and solute recognition and binding have
all been implicated as molecular pathologies associated with ABC-
transporter mutations [15–18].
The trafficking of multiple ABC transporters is regulated, in
part, by C-terminal PDZ (PSD95/Dlg/ZO-1) ligands. [19–24]
The short C-terminal peptide sequences are bound by PDZ
domain-containing proteins. These multi-domain proteins facili-
tate protein-protein interactions by acting as scaffolds, binding
their respective PDZ ligands and holding their partners in close
physical proximity. These associations have been shown to
regulate protein activity, protein stability and protein mobility in
the membrane. [22–25] Multiple modes of peptide binding have
been ascribed to different classes of PDZ domains. [26] Specificity
for these interactions is thought to come from both the sequences
of the different ligands and subcellular localization of their PDZ-
domain containing protein partners. Within the ABCC subfamily
of human ABC-transporters, multiple PDZ ligands have been
identified and characterized. Alteration to these sequences results
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in mislocalization, reduced stability and increased mobility in
other members of the ABCC subfamily, including the multi-drug
transporters and CFTR [22,25,27–29].
To evaluate the role of the C-terminal sequence from ABCC6,
mutations to the PDZ-like sequence were generated and protein
biosynthesis, trafficking and turnover were analyzed in both non-
polarized and polarized cells. Deletion of the C-terminal six amino
acids, which constitute a PDZ-like ligand sequence, resulted in a
significant decrease in steady state levels of ABCC6. These
changes were the result of mislocalization within the cell and an
increase in protein degradation. In polarized cells, deletion of the
C-terminal residues resulted in inefficient targeting to the
basolateral membrane. These data demonstrate that the non-
canonical PDZ-like sequence found at the C-terminus of ABCC6
contributes to its regulation in the cell. Characterization of the
trafficking and regulation of ABCC6 by its physiological binding
partners will provide additional insight into the molecular
regulation of ABCC6 in normal physiology and the pathophys-
iology associated with PXE.
Materials and Methods
Cloning and Site-directed Mutagenesis
The full-length ABCC6 open reading frame was cloned into
pcDNA3.1 (Invitrogen) for CMV-driven expression in mammalian
cells. PCR-based site directed mutagenesis was used to introduce
specific mutations in the pcDNA-ABCC6 plasmid (QuikChange,
Stratagene). The BLAP tagged ABCC6 protein was constructed by
PCR insertion of the acceptor peptide sequence (GLNDIFEAQ-
KIEWHE) after Pro4 in the native ABCC6 sequence in the
pcDNA3.1 vector. The pBUDD-BirA-KDEL plasmid was a
generous gift from Dr. Daniel C. Devor (University of Pittsburgh).
Site directed mutagenesis and full-length sequences were con-
firmed by automated DNA sequencing.
Cell Culture and Western Blotting
HEK and MDCK cells were obtained from ATCC. HEK293
cells were routinely maintained in DMEM (Gibco) supplemented
with 10% v/v FBS, 100 units/ml penicillin and 100 mg/ml
streptomycin at 37uC in a 5% CO2 environment. MDCK cells
were routinely maintained in aMEM (Gibco) supplemented with
10% v/v FBS, 100 units/ml penicillin and 100 mg/ml streptomy-
cin at 37uC in a 5% CO2 environment. Cells were transfected
using either Fugene6 (Promega) or XtremeGene9 (Roche) lipid
transfection reagents. For HEK293 cells, cells were transfected
following manufacturers’ protocols and lysed 48–72 hours post-
transfection for analysis. Cell surface biotinylation experiments
were performed using Sulfo-NHS-Biotin (Pierce) following man-
ufacturers’ protocols. For expression in MDCK cells, cells were
transfected at 80% confluence on 0.2 micron Transwell inserts
(Costar). Cells were allowed to polarize for 4 days prior to analysis.
Polarization was confirmed by staining with the tight junction
marker ZO-1. For western blotting, cells were lysed in RIPA
(Millipore) and lysates were cleared by centrifugation at 21,000 G
for 10 minutes at 4uC. Lysates were separated by SDS-PAGE on
Tris-glycine gels and transferred to PVDF membrane. At least 3
independent experiments were performed for each analysis and
representative western blots are shown.
Antibodies and Labeling Reagents
Western blotting and immunofluorescence for ABCC6 were
performed using the rat monoclonal a-ABCC6 antibody M6II-7
or M6II-31 (Santa Cruz), which were raised against a portion of
TMD2. Polyclonal a-ZO1 antibody (Cell Signalling) was used in
immunofluorescence to confirm polarization of the MDCK cells.
A mouse monoclonal a-tubulin antibody (Sigma-Aldrich) or a-
PARP1 (GeneTex) were used for loading controls. AlexaFluor488
and 555-conjugated streptavidin were used to label the BLAP-
containing ABCC6 constructs at the cell surface (Invitrogen).
Phalloidin and WGA (Invitrogen) were used as cell surface
markers; DAPI (Sigma-Aldrich) was used to stain nuclei.
Immunofluorescence, Fluorescence Labeling and
Fluorescent Microscopy
HEK293 and MDCK cells expressing the pcDNA-ABCC6
proteins were utilized for immunofluorescence. Following expres-
sion, cells were washed three times in PBS at 4uC and fixed using
2% PFA in PBS for 10 minutes at 4uC. Cells were blocked with
BSA and stained using the antibodies described above. Alexa-
Fluor-conjugated secondary antibodies were used to visualize the
ABCC6 and ZO1 proteins (Invitrogen). Immunofluorescence was
visualized on either an Olympus IX81 fluorescence microscope or
a Fluoview 1000 confocal microscope. Immunofluorescence
images were collected from multiple fields from at least four
independent experiments. At least 16 fields were evaluated for
each of the conditions evaluated. Blind experiments were
performed to validate the differences in observed trafficking and
expression of the various ABCC6 constructs.
The pcDNA-BLAP-ABCC6 protein was utilized to evaluate cell
surface ABCC6. HEK293 or MDCK cells were seeded onto glass
coverslips pretreated with poly-lysine (Sigma). Cells were co-
transfected with the pcDNA-BLAP-ABCC6 plasmid and the
pBUDD-BirA-KDEL plasmid and proteins were allowed to
express for 24–48 hours in HEK293 cells and for 5 days in
MDCK cells. Following expression, the media was aspirated from
the cells and the cells were washed with PBS with 2% BSA on ice.
Alexafluor conjugated streptavidin was incubated with the cells in
a solution of PBS and 2% BSA for 10 minutes on ice. The labeling
mix was aspirated and the cells were washed three times with PBS
to remove unbound streptavidin. The cells were either fixed with
2% PFA in PBS or returned to the CO2 incubator for kinetic
experiments and fixed after specific incubation periods.
NBD Protein Expression and Analysis
The boundaries of the NBD2 domain were predicted utilizing
multiple sequence alignments and structural analysis of extant
NBD crystal structures. The predicted coding sequence was PCR
amplified and cloned into the pSmt3 vector, which includes an N-
terminal 6x His tag and the yeast SUMO protein, Smt3, to aid in
solubility. [30] Expression and purification followed procedures
previously described for the NBDs from CFTR. [31,32] E coli
BL21 (DE3) cells were transformed with the expression plasmids
and single colonies were picked to grow an inoculum overnight at
37uC. A one liter expression culture of either the wildtype or
mutant NBD2 was inoculated and the cultures were grown at
37uC until an OD600 of ,1.0 in LB broth. Protein expression was
induced with 1 mM IPTG and the cultures were shifted to 15uC
for expression overnight. Cells were harvested by centrifugation
and lysed by sonication in ice cold binding buffer (50 m Tris,
150 mM NaCl, 10% w/v glycerol, pH 7.6) with 2 mM ATP and
1 mM beta-mercaptoethanol. The lysate was clarified by centri-
fugation (40,000 G RCF, 4uC, 40 minutes) and the soluble fraction
was loaded onto a Ni-NTA column (GE HealthSciences) pre-
equilibrated in binding buffer lacking ATP. The protein was
washed and eluted in binding buffer supplemented with 60 or
400 mM imidazole, respectively. Fractions were collected and
samples containing NBD2 protein were immediately supplement-
ed with 2 mM ATP and 1 mM DTT (final concentrations). The
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fractions were pooled and loaded onto a HiPrep Sephacryl S-300
gel filtration column (GE HealthSciences) equilibrated with
binding buffer supplemented with 2 mM ATP and 1 mM DTT.
Fractions containing NBD2 were pooled and digested with Ulp1
to liberate the N-terminal His-Smt3 tags and the protein was
applied to a Ni-NTA column equilibrated with binding buffer
supplemented with 2 mM ATP and 1 mM DTT. The Ulp1 and
Smt3 proteins bound to the Ni-NTA column via their respective
His tags and the flow through containing NBD2 as collected,
concentrated and stored at280uC prior to use. Circular dichroism
(CD) spectroscopy and analytical gel filtration chromatography
(GFC) were performed to assess changes in secondary structure
and hydrodynamic radius. CD spectra were collected on a Jasco
810 spectropolarimeter, as previously described. [33] Analytical
GFC was performed using a Superdex S75 10/300 GL (GE
HealthSciences) column to evaluate changes in hydrodynamic
radius.
Results
C-terminally Regulated Trafficking of the ABCC6 Protein
ABCC6 is a member of the ABC-transporter family of proteins
and is composed of five domains (Figure 1A). [34] Three
transmembrane domains and two cytosolic, nucleotide-binding
domains are encoded by a single polypeptide and putatively form
the functional unit for transport. The two core transmembrane
domains (TMD1 and TMD2) putatively provide the channel for
substrate movement across the membrane. In addition an
accessory transmembrane domain (TMD0) is located at the N-
terminus. The function of this domain is unknown. Two
nucleotide-binding domains are located intracellularly and are
associated with ATP binding and hydrolysis, providing the energy
for substrate transport.
A growing number of disease-associated mutations have been
identified in the open reading frame of ABCC6. [5,6,35–37]
Sequence analysis of the C-terminus shows a high degree of
similarity to the PDZ ligand sequence identified in other ABCC
family members (Figure 1B). These sequences have been shown to
regulate subcellular localization, membrane stability, membrane
motility and protein-protein interactions in other ABCC family
members. [23–25,27] The PDZ-like sequence in ABCC6 is highly
conserved across species and includes the canonical Type I PDZ
motif (acidic-polar-X-hydrophobic) found in closely related
proteins and a C-terminal valine. [25,38] The presence of this
Val would putatively alter the binding of the PDZ ligand with its
cognate partner in standard Type I PDZ ligand-domain interac-
tions. However, multiple binding modes have been described
structurally and diverge from the classical Type I binding. It is
possible that the C-terminal valine would be accommodated in
other binding modes with PDZ-domain containing proteins.
[39,40].
To investigate the role of this PDZ-like sequence in the
regulation of ABCC6 biosynthesis and trafficking, the C-terminal
sequence was deleted by PCR-based site directed mutagenesis and
protein trafficking was assessed by western blotting after expression
in HEK293 cells. The wildtype protein expressed robustly and was
detected as two distinct bands by western blotting resulting from
changes in glycosylation occurring in the ER and Golgi (Figure 1C,
D). Under steady state conditions, the lower molecular weight
species, band B, was found to be the core glycosylated, ER form of
the protein. The higher molecular weight band was insensitive to
EndoH but sensitive to PNGaseF digestion, consistent with protein
modification by complex glycosylation in the Golgi. To further
confirm these species were the result of changes in glycosylation,
the single glycosylation site was mutated (N15D) and expressed.
Digestion with both EndoH and PNGaseF resulted in no changes
in electrophoretic mobility. Migration of the single N15D protein
band was consistent with the fully deglycosylated protein, band A,
in the wildtype ABCC6 expressing cells.
Deletion of the six C-terminal amino acids (D6-COOH), which
includes the complete PDZ ligands found in other ABCC family
members, showed dramatic changes in both protein biosynthesis
and protein trafficking as measured by western blotting (Figure 1C,
D). Steady state D6-COOH protein levels were reduced relative to
the wildtype protein (Figure 1C). Both band B and band C species
were reduced relative to wildtype. In addition, the quantity of
band C protein was significantly decreased relative to the quantity
of the band B form, consistent with either rapid turnover of the
fully glycosylated protein or a decrease in biosynthetic efficiency
and trafficking.
Cell surface biotinylation was used to assess the plasma
membrane expression of ABCC6. Cell surface biotinylation of
cells expressing the wildtype ABCC6 showed the presence of
protein at the surface of HEK293 cells (Figure 1E). The protein
appeared as a single band, consistent with the trafficking of the
complexly glycosylated ABCC6 to the plasma membrane.
Similarly, the D6-COOH ABCC6 protein also showed cell surface
localization by biotinylation. As with the analysis of total steady-
state protein levels, the quantity of cell surface D6-COOH ABCC6
was reduced when compared to the wildtype protein. Control
cells, which were mock transfected, showed no detectable
production of ABCC6 in both the total and cell surface fractions.
Tubulin was present only in the total lysate fractions, consistent
with its intracellular localization and protection from the
biotinylation reaction.
Immunofluorescence was used to verify the subcellular locali-
zation of these proteins. The wildtype protein showed robust and
diffuse expression in HEK293 cells, consistent with its trafficking
through the secretory pathway and to the membrane (Figure 1F).
Membrane localization was confirmed by colocalization with
phalloidin. In contrast, the D6-COOH protein showed decreases
in the number of stainable cells and the fluorescence intensity in
cells expressing the protein (Figure 1F). Further, cells expressing
the D6-COOH protein showed predominantly intracellular
fluorescence, consistent with retention of the mutant in the ER
seen by western blotting. Colocalization studies with BiP indicated
the mutant protein was localized predominantly to the ER (data
not shown). These data were consistent with the changes in steady
state signal seen by western blotting of the D6-COOH protein and
the reduction in complexly glycosylated species. No observable
changes in immunofluorescence were seen between the wildtype
and N15D glycosylation mutant (data not shown).
Finally, to assess trafficking in polarized cells, the wildtype and
D6-COOH proteins were expressed in MDCK cells and assessed
by immunofluorescence. Previous reports of wildtype ABCC6
trafficking indicate the ABCC6 protein is targeted to the
basolateral membrane. [41] Consistent with this, the wildtype
ABCC6 showed preferential targeting to the basolateral mem-
brane in the MDCK cells (Figure 1G). Polarization of the MDCK
monolayer was confirmed by staining with ZO1. Deletion of the
PDZ-like sequence resulted in decreased targeting of the ABCC6
protein to the basolateral membrane and an increase intracellular
protein. The predominant population of the D6-COOH protein
colocalized with BiP, consistent with its accumulation in the ER
and the immunofluorescence seen in HEK293 cells (data not
shown).
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Figure 1. Alteration of ABCC6 trafficking by the PDZ-like C-terminus. To evaluate the potential role of the PDZ-like sequences at the C-
terminus of ABCC6, wildtype and mutant proteins were expressed in HEK293 cells and evaluated by western blotting and immunofluorescence. A, a
cartoon illustrating the domain organization and topology of ABCC6 is shown. ABCC6 contains three transmembrane domains and two nucleotide-
binding domains. The single glycosylation site is represented as Y in the extracellular N-terminus. The insertion site for the biotin ligase acceptor
peptide is also shown in the N-terminus at proline 4. B, a sequence alignment of known PDZ-containing ABCC family members is shown. The Type I
Regulation of ABCC6 Stability by a C-terminal Sequence
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NBD2 Structure
Based on comparisons with the structures of other NBD
proteins, the PDZ-like sequence is located at the C-terminus of the
second NBD in ABCC6 and is not predicted to contribute to the
core of the NBD fold. [31,32,42] To evaluate the possibility that
altered NBD structure resulted from the D6-COOH deletion, the
NBD2 domain was expressed and purified from E. coli for in vitro
structural analyses. The wildtype and mutant NBD2 proteins
expressed robustly and were purified using Ni-NTA and gel
filtration chromatography. Changes in secondary structure of the
purified NBD2 proteins were first evaluated using CD spectros-
copy. The wildtype NBD2 proteins produced CD spectra
consistent with mixed a/b-secondary structure (Figure 2A). These
spectra were qualitatively consistent with those of solved crystal
structures of other NBD proteins. [43] The D6-COOH NBD2
protein spectra showed no significant deviation from those of the
wildtype NBD2 proteins, consistent with its folding to a similar
mixed a/b structure. To evaluate the tertiary structure of the
wildtype and mutant NBD2 proteins, hydrodynamic radii were
measured using analytical GFC (Figure 2B). The wildtype protein
eluted as a single symmetrical peak, consistent with a protein of
,25 kDa molecular weight. The elution chromatographs showed
no significant protein in either the column void or outside of the
monomer peak, consistent with a highly purified and homoge-
neous sample. Elution volumes were calibrated using GFC
standards to confirm apparent molecular weights. The mutant
NBD2 protein eluted with a symmetrical profile similar to that of
the wildtype NBD2. No significant protein was seen in the column
void or outside of a single predominant peak corresponding to the
monomeric NBD.
Low Temperature Rescue of the Truncated ABCC6
Protein
To further elucidate the effects of the D6-COOH mutant, the
ABCC6 proteins were expressed in HEK293 cells at low
temperature. Previous studies of multiple membrane proteins
suggest that biosynthetic and localization defects can often be
corrected by expression at sub-physiological temperatures. [44–
47] Expression of the wildtype and mutant ABCC6 proteins was
performed at 27uC for 72–96 hours. Western blotting of the
wildtype and mutant ABCC6 proteins showed dramatic changes
in expression at low temperature. The wildtype protein expressed
robustly, though changes in the relative levels of band B and Band
C were observed (Figure 3A). Specifically, the quantity of band B
protein was consistently increased when compared to the quantity
of band C wildtype protein. This was consistent with an
accumulation of the ER-associated form of the protein. In
addition, the mutant protein showed an increase in both band B
and band C forms of the protein (Figure 3A). The increase in
expression was seen as both an increase in total steady state protein
and an accumulation of the upper molecular weight, band C
species.
The accumulation of the band C form of the protein was
consistent with an increase in protein trafficking or a stabilization
of the mature form of the protein in post-ER compartments.
Immunofluorescence revealed similar changes in subcellular
localization of the wildtype and mutant ABCC6 proteins
(Figure 3B). The wildtype protein showed subtle increases in the
quantities of intracellular protein by immunofluorescence. More
strikingly, the mutant protein showed an increase in total ABCC6
protein staining. In addition, the D6-COOH protein appeared
more diffuse and colocalization with membrane markers was
increased after expression at 27uC. These data were consistent
with an increase in the mutant protein at the cell surface.
C-terminal Regulation of ABCC6 Degradation
The changes in steady state protein levels were consistent with
an increase in protein turnover associated with the D6-COOH
mutation. To further evaluate how changes in protein turnover
may be regulated by the PDZ-like sequence, cyclohexamide chase
experiments were performed on HEK293 cells expressing
ABCC6. Cells expressing either the wildtype or mutant protein
were harvested at specific timepoints after cyclohexamide addition
and evaluated by western blotting (Figure 4A). Cyclohexamide
addition had little effect on the synthesis of either the wildtype or
D6-COOH protein as judged by the relative band C - band B ratio
at the zero hour timepoint. Wildtype band C protein levels
appeared unaltered across the 18-hour timecourse of cyclohex-
amide treatment as no significant decrease in band C was seen by
western blotting (Figure 4B).
In contrast, the D6-COOH protein showed increased protein
turnover during the cyclohexamide treatment timecourse. At the
zero timepoint, both band B and band C protein were observed
for the D6-COOH protein (Figure 4A). The band B protein did
not appear in subsequent timepoints, consistent with either its
maturation to the band C form or its degradation from the ER.
However, the band C D6-COOH protein showed increased
degradation across the 18-hour timecourse of cyclohexamide
treatment (Figure 4B). At eight hours, the D6-COOH protein
showed a ,20% decrease in band C, as compared to the zero
hour timepoint. At 18 hours, the quantity of band C D6-COOH
protein was reduced by greater than 80%, as compared to the zero
hour timepoint. The increase in protein turnover suggested that
increased rates of degradation of the D6-COOH protein
consensus is shown above the alignment as is represented as: A, acidic; P, polar, X, any; and H, hydrophobic amino acids. The PXE-associate G1501S
site is highlighted in red. C, representative western blots of the wildtype and D6-COOH ABCC6 proteins are shown after expression in HEK293 cells.
The core and complexly glycosylated species are indicated on the left by B and C, respectively. Two exposures are shown for the D6-COOH to
illustrate the formation of both band B and C at low levels in the mutant protein. D, endoglycosidase assays confirm the glycosylation state and
differential electrophoretic migration of the ABCC6 proteins. The differential digestion of the band C protein by EndoH and PNGaseF demonstrates
complex glycosylation, consistent with trafficking through the Golgi. The N15D substitution blocks N-linked glycosylation and is a reference for the
unglycosylated wildtype and D6-COOH proteins. E, representative western blots from cell surface biotinylation experiments are shown. Cell surface
expression is shown for cells mock transfected (CNTL) or transfected with wildtype or D6-COOH ABCC6, Cell Surface. Whole cell lysates are shown,
Total, from samples prior to streptavidin pull-down. The control samples are taken from non-adjacent wells on a single gel/film. F,
immunofluorescence images of the wildtype and D6-COOH proteins are shown. The ABCC6 proteins are shown in green, phalloidin is shown in
red, and DAPI is shown in blue. Colocalization of the ABCC6 protein with phalloidin is consistent with ABCC6 trafficking to the cell surface in the
wildtype protein and is decreased by the D6-COOH mutant. G, immunofluorescence images of the wildtype and D6-COOH ABCC6 proteins are shown
after expression in polarized MDCK cells. The wildtype ABCC6 protein localizes to the basolateral membrane in polarized MDCK cells, left. The D6-
COOH protein shows significant intracellular staining and a loss of basolateral targeting in MDCK cells, right. Both X–Y, top, and X–Z, bottom, images
are shown. For G, ABCC6 is stained in green and ZO1 is shown in red. Western blots are representative of samples from at least three independent
experiments.
doi:10.1371/journal.pone.0097360.g001
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contributed to the changes in expression seen by western blotting
and immunofluorescence under steady state conditions.
Plasma Membrane Turnover of ABCC6
To further evaluate changes ABCC6 dynamics, a biotin ligase
acceptor peptide (BLAP) was introduced into the N-terminus of
the ABCC6 proteins (Figure 1A). Previous studies have shown that
the BLAP tag is selectively modified by the BirA biotin ligase and
can be used to efficiently label proteins that include this specific
peptide sequence. [48,49] To accomplish labeling, the ABCC6-
BLAP proteins were co-expressed with BirA that has been fused
with an ER-localization (KDEL) sequence or labeled with purified
BirA at the cell surface. When both the ligase and tagged proteins
are co-expressed, the nascent polypeptide is biotinylated by the
BirA ligase during biosynthesis and ER membrane integration.
The cell surface biotinylated protein can then be labeled by
addition of membrane impermeant, fluorescently-conjugated
streptavidin.
Steady-state expression of the wildtype and D6-COOH BLAP
proteins was assessed by western blotting and immunofluores-
cence. As seen with the untagged ABCC6 proteins, the wildtype
protein trafficked with high efficiency through the secretory
pathway. Western blotting confirmed strong band C expression of
the BLAP tagged wildtype ABCC6 (Figure 5A). The D6-COOH
BLAP ABCC6 showed a dramatic reduction in total expression
compared to wildtype. In addition, the relative quantities of band
C and band B were altered in the D6-COOH mutant when
compared with wildtype. These changes were consistent with those
seen in the untagged ABCC6 proteins (Figure 1). Cell surface
detection of the protein after co-expression with KDEL-BirA,
visualized by extracellular application of an AlexaFluor conjugated
streptavidin, confirmed the cell surface expression of the wildtype
protein (Figure 5B). As with the biotinylation and immunofluo-
rescence of the untagged D6-COOH ABCC6 protein, the BLAP
tagged mutant showed reduced cell surface expression with fewer
cells and lower fluorescence signal evident for the mutant. These
results suggested the presence of the BLAP tag had no discernible
effect on the behavior of the wildtype and mutant ABCC6
proteins.
Using this system, we assessed the lifetime of the plasma
membrane resident BLAP-ABCC6 proteins using both fluores-
cence and western blotting of the ABCC6-biotin-streptavidin
complex, as previously described. [49] Pulse-chase cell surface
labeling of the wildtype and D6-COOH proteins was accom-
plished by sequential labeling using two AlexaFluor-conjugated
streptavidin proteins. Cells were labeled on ice with an Alexa-
Fluor-488 conjugated streptavidin and the excess streptavidin was
removed by washing with PBS. The initial labeling corresponded
to the cell surface ‘‘pulse,’’ selectively tagging the plasma
membrane resident ABCC6 protein. The cells were then
incubated for designated periods – the ‘‘chase’’ - at 37uC before
being labeled using an AlexaFluor-555 conjugated streptavidin,
washed and fixed for visualization. The second labeling facilitated
the identification of the cell surface and demonstrated continued
expression and trafficking of ABCC6 during the experimental
timecourse.
The wildtype ABCC6 protein showed robust cell-surface
labeling (Figure 5C) at the initial timepoint (0 hours) with the
AlexaFluor-488-conjugated streptavidin. The inability to detect
significant AlexaFluor-555 label at the zero timepoint suggested
that the vast majority of plasma membrane ABCC6 was bound by
the AlexaFluor-488-conjugated streptavidin. At four, eight and 18
hours after the AlexaFluor-488 ‘‘pulse,’’ the wildtype protein was
partially endocytosed, as evidenced by the internalization of the
AlexaFluor-488 label. This relocalization was confirmed by the
visualization of AlexaFluor-555 labeled ABCC6 at the cell surface.
By 18 hours the majority of plasma membrane ABCC6 initially
labeled at the zero time point appeared to have been internalized
and/or degraded. The loss of fluorescence after internalization
likely resulted from both dilution of the fluorophore from the
plasma membrane into multiple intracellular compartments and
degradation of the streptavidin conjugate.
In contrast, the D6-COOH protein showed increased internal-
ization and degradation relative to the wildtype protein
(Figure 5C). Cell surface labeling of the mutant protein was less
robust than the wildtype at the initial timepoint. Additionally, by 4
hours the majority of mutant ABCC6 protein had been
internalized and degraded, as evidenced by a loss of green
Figure 2. Structural characterization of wildtype and D6-COOH NBD2. To evaluate potential changes in ABCC6 NBD2 resulting from the C-
terminal deletion, NBD2 was expressed and purified for in vitro analysis. A, CD spectroscopy was used to evaluate changes in the secondary structure
of the mutant NBD2. Spectra were collected from 260 to 198 nm and corrected for buffer absorbance. The traces were smoothed using a window of
5 nm. The wildtype NBD2, black circles, shows a mixed a/b secondary structure qualitatively consistent with known structures of NBD proteins. The
D6-COOH mutant NBD2, open circles, shows no significant differences in CD spectra. B, analytical gel filtration was used to evaluate changes in
hydrodynamic radii of the wildtype and mutant NBD2 proteins. The wildtype protein eluted as a single symmetrical peak at ,12.2 mls, consistent
with a protein of ,25,000 Da MW. The mutant proteins eluted similarly, with a peak at 12.2 mls. No discernible differences in either CD or GFC could
be detected between the wildtype and mutant proteins.
doi:10.1371/journal.pone.0097360.g002
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fluorescence. By eight and 18 hours, the ABCC6 protein labeled at
the initial timepoint was undetectable. As with the wildtype
protein, D6-COOH ABCC6 streptavidin-conjugated AlexaFluor-
555 labeling after the ‘‘chase’’ period facilitated identification of
the cell surface and demonstrated continued expression and
trafficking of the ABCC6 protein.
To verify the turnover of these cell surface ABCC6 proteins
biochemically, western blots of the streptavidin-bound BLAP-
ABCC6 protein were evaluated. Previous studies have shown that
Figure 3. Rescue of ABCC6 trafficking by low temperature expression. Low temperature expression was used to further evaluate ABCC6
trafficking in HEK293 cells. A, western blots showing the expression of the wildtype and D6-COOH ABCC6 proteins at 37uC and 27uC. Expression of the
wildtype protein at 27uC results in an increase in relative quantities of the core glycosylated, band B protein. Expressing the mutant protein at low
temperature resulted in an increase in complexly glycosylated protein (band C), consistent with an increase in the formation or stabilization of this
protein. B, indirect immunofluorescence of ABCC6 confirming the trafficking of the wildtype and mutant proteins is shown. Consistent with the
western blotting, expression at low temperature results in redistribution of the mutant protein towards the plasma membrane. ABCC6 is shown in
green, phalloidin is shown in red and DAPI is shown in blue.
doi:10.1371/journal.pone.0097360.g003
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the streptavidin-biotin association is resistant to SDS, with the
biotin and streptavidin remaining complexed after SDS-PAGE
analysis. [49] The resulting size shift, associated with the ABCC6-
streptavidin complex, effectively separates the labeled and
unlabeled proteins when separated by PAGE. Thus, the cell
surface pool of ABCC6 can be analyzed independent of the
internal pools of protein. Cells were labeled with streptavidin and
incubated for up to eight hours. Cells were harvested at specific
timepoints and the lysates were subjected to SDS-PAGE and
western blotting (Figure 5D). The wildtype protein showed strong
expression at the initial timepoint and appeared to decay after
approximately 4 hours. At eight hours, the wildtype protein was
reduced, but still readily detectable. The mutant protein showed a
decrease in total expression and an increase in the rate of
degradation. By four hours, the mutant protein showed significant
reduction in signal and was undetectable at eight hours. The
intracellular protein PARP-1 (110 kDa) was used as a loading
control to facilitate simultaneous detection of the streptavidin-
ABCC6 complex and the control.
Mechanisms of ABCC6 Degradation
To further evaluate the mechanisms associated with the D6-
COOH turnover and determine where in the cell this turnover
occurs, lactacystin and leupeptin/pepstatin were used to probe
cellular degradation pathways. Lactacystin was utilized to block
the proteasome, which is the principle degradation machine
associated with ER-associated degradation (ERAD). Inhibition of
the proteasome by lactacystin treatment showed minimal effects
on the maturation of the wildtype protein, as evaluated by western
blotting (Figure 6A). Subtle changes in band C quantities were
seen after treatment with lactacystin. No significant accumulation
of band B protein was seen in cells expressing the wildtype protein,
consistent with its trafficking from the ER to the Golgi. In contrast,
the band B D6-COOH protein accumulated with lactacystin
treatment, consistent with a reduction in ERAD. No significant
changes in band C protein were seen with lactacystin treatment for
the D6-COOH protein. The accumulation of band B and lack of
band C formation suggested that inhibiting the proteasome did not
facilitate trafficking of the mutant protein to the Golgi and post-
Golgi compartments. Immunofluorescence confirmed the accu-
mulation of intracellular D6-COOH protein (Figure 6B).
To evaluate protein turnover from the cell surface, a
combination of leupeptin and pepstatin were utilized to block
lysosomal degradation. Treatment with leupeptin/pepstatin re-
sulted in an increase in band C protein for both the wildtype and
D6-COOH under steady state conditions (Figure 6C). In a dose-
dependent manner, increasing leupetin doses resulted in increasing
band C protein levels. Band B protein levels for the D6-COOH
protein appeared unaffected by these treatments, consistent with
its degradation by the proteasome seen in Figure 6A. The
increased accumulation of band C D6-COOH protein suggested
that a population of this protein trafficked out of the ER and into
post-Golgi compartments, where it was degraded in the lysosome.
Similarly, when evaluated by immunofluorescence, both wildtype
and D6-COOH showed increased intracellular accumulation
(Figure 6D). The accumulation of intracellular protein seen by
immunofluorescence was consistent with western blots of ABCC6
and demonstrated that the post-Golgi pool of ABCC6 was
degraded by the lysosome.
Discussion
The regulation of ABC transporter trafficking and activity is
complex, requiring multiple folding and assembly steps to form the
functional transporter. [50–52] In addition to the biosynthetic
processes, ABC transporter localization and stability are regulated
by multiple protein sequences. [24,38,53,54] Among these, PDZ
ligands have been shown to contribute to protein localization and
stability at the plasma membrane. [29,55–57] Given the apparent
similarity of the ABCC6 C-terminal sequence to other PDZ-
containing ABCC transporters and the presence of a disease-
associated mutation within this region, we chose to evaluate the
role of this sequence in the expression and regulation of ABCC6.
Previous studies have demonstrated that the C-terminal
sequences in other ABC transporters play critical roles in the
trafficking, localization and function of these proteins. [55–58]
Similarly, the deletion of the PDZ-like sequence in ABCC6
suggested that this region of the protein also contributed
significantly to the biosynthesis and trafficking of the protein.
Figure 4. Impact of the C-terminus on ABCC6 turnover. Protein turnover was evaluated by cyclohexamide chase experiments after expression
in HEK293 cells. A, western blots of the wildtype and D6-COOH proteins are shown after 0, 4, 8, and 18 hours of cyclohexamide treatment. The
wildtype protein shows minimal changes after 18 hours of cyclohexamide treatment, while the mutant is decreased by ,80% over this timecourse.
The loss of band B protein in the mutant is consistent with the inhibition of new ABCC6 synthesis over the timecourse of treatment resulting from
cyclohexamide treatment. B, summary data for cyclohexamide chase experiments are shown. Between 8 and 18 hours of cyclohexamide chase, the
D6-COOH mutant protein is diminished by ,80% relative to the wildtype protein. Data shown are mean +/2 standard deviation from n= 3
experiments.
doi:10.1371/journal.pone.0097360.g004
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Figure 5. Regulation of cell surface stability by the C-terminus. Cell surface stability was evaluated by selective biotinylation of the ABCC6
protein using the BirA ligase and acceptor peptide in the extracellular N-terminus (see Figure 1A). A, western blots of the wildtype and D6-COOH
ABCC6 protein with the BLAP tag are shown. The inclusion of the BLAP tag in the N-terminus had no detectable effect on the trafficking of the
wildtype or mutant ABCC6 proteins evaluated by western blotting. B, fluorophore-conjugated streptavidin was applied to the culture media and cell
surface expression of the BLAP ABCC6 protein was evaluated by fluorescence microscopy. Consistent with western blotting, no detectable differences
were seen between the BLAP tagged and untagged ABCC6 proteins. The wildtype protein expressed robustly in HEK 293 cells, while the mutant
protein was only labeled in a small fraction of cells transfected. C, fluorescence analysis of the timecourse of ABCC6 internalization and degradation
from the cell surface is shown. The BLAP tagged proteins were sequentially labeled with fluorophore-conjugated streptavidin. Initial staining, time
zero, was performed using AlexaFluor-488, green, and secondary labeling was performed using AlexaFluor-555, red. The internalization and
degradation of ABCC6 could be seen over the course of 4–18 hours as the loss of green signal. D, western blots of cell surface labeled ABCC6 are
shown. Streptavidin was incubated extracellularly on intact HEK293 and the BLAP-tagged ABCC6 protein was bound and washed. The lystes were
subjected to SDS-PAGE and western blotting. The conjugated ABCC6-streptavidin complex could be distinguished readily from the total ABCC6
protein, allowing for the evaluation of plasma-membrane ABCC6 protein. Proteins were labeled, washed and incubated for zero to eight hours before
lysis. Negative controls included expression of the BLAP-ABCC6 protein without streptavidin treatment (C1) and mock-transfected HEK293 cells
treated with BirA and streptavidin (C2). Both negative controls showed no staining, consistent with specific detection of labeled BLAP-tagged ABCC6
in the experimental samples.
doi:10.1371/journal.pone.0097360.g005
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Figure 6. Impact of the C-terminus on ABCC6 degradation. ABCC6 degradation was evaluated after treatment with a proteasome inhibitor
(lactacystin) or a combination of lysosomal protease inhibitors, (leupeptin and pepstatin) and assessed by western blotting. A,B, inhibition of the
proteasome by lactacystin results in an accumulation of the ER-resident, band B protein in the mutant ABCC6. A, increasing lactacystin concentrations
from 0–10 mM, results in an accumulation of the band B form of the mutant ABCC6 protein as seen by western blotting. No increase in the formation
of the band C, complexly glycosylated protein is seen for either wildtype or mutant ABCC6 with lactacystin treatment. B, immunofluorescence of the
ABCC6 proteins reveals the wildtype and mutant accumulate after proteasome inhibition, but the mutant fails to redistribute to the cell surface.
ABCC6 is shown in green, phalloidin is shown in red and DAPI is shown in blue. C,D, lysosomal inhibition results in an increase in the complexly
glycosylated, band C protein for both wildtype and mutant ABCC6. C, a dose response of leupeptin/pepstatin treatment is shown from 0–100 mM
leupeptin treatment in the presence of 1 mg/ml pepstatin. Increasing pepstatin concentrations resulted in an increase in the band C ABCC6 protein.
D, immunofluorescence of HEK293 cells treated with leupeptin/pepstatin is shown. Treatment with leupeptin/pepstatin resulted in an increase in the
quantities of ABCC6 intracellularly. ABCC6 is shown in green, phalloidin is shown in red and DAPI is shown in blue.
doi:10.1371/journal.pone.0097360.g006
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Removal of the C-terminal six amino acids, predicted to contain
the residues required for a PDZ-domain interaction, resulted in
decreased steady state protein levels and changes in protein
localization in both polarized and non-polarized cells (Figure 1).
These changes appeared to decrease total protein expression
resulting from an increase in protein degradation (Figure 4, 5).
The changes in degradation were likely the result of increased
protein turnover in the ER and at the plasma membrane, as the
core glycosylated protein and the complexly glycosylated protein
were reduced by the C-terminal truncation. Both forms could be
alternately stabilized by protease inhibition. The ER associated
form was most strongly stabilized by inhibition of the proteasome
while the post-ER pool of protein was most strongly stabilized by
inhibition of the lysosome (Figure 5). These changes in protein
degradation did not appear to be caused by gross changes in the
local structure of the NBD, as purification of the wildtype and
mutant NBD2 were similar. The local structural properties
assessed spectrophotometrically and hydrodynamically were also
similar for both NBDs (Figure 2). Additional work is required to
assess the possibility that global changes might be propagated into
the ABCC6 structure through altered domain-domain contacts.
However, these data are consistent with previous reports of
regulated ABC transporter trafficking by PDZ associations in the
secretory pathway. [54,59].
Previous studies have shown that PDZ sequences contribute to
the regulated trafficking of other proteins, including ABC
transporters, though the exact roles of these sequences vary by
protein. In CFTR (ABCC7) the PDZ sequences regulate protein
localization and stability in the plasma membrane, with little
influence on the biosynthetic processing or trafficking of the
protein. [27,38] In contrast, removal of the PDZ sequence from
ABCC2 (cMOAT, MRP2) can alter either localization to the
apical membrane or changes in protein trafficking through the
biosynthetic pathway. [57,58] Further, these processes may be
regulated by phosphorylation of residues within the PDZ
sequence, providing a cellular mechanism to dynamically regulate
these associations. [23] Similar effects on trafficking and localiza-
tion have been reported for NMDA receptors, K+-channels, and
aquaporin channels, among others. [20,55,56] These results are
consistent with models wherein PDZ ligands are critical regulators
of intracellular protein-protein interactions along the secretory and
endocytic pathways as well as protein localization anchors at the
plasma membrane. [24].
Whether this sequence serves as a bona fide PDZ sequence that
binds a PDZ-domain containing protein or serves as a target for
other cellular proteins/processes is yet to be elucidated and
deserves further investigation. However, a single PXE patient in
which the G1501S mutation was found was reported to show
phenotypic abnormalities in the eye (bleeding/scarring) and mild
presentation in the skin (papules/bumps), but presented without
apparent GI, vascular or cardiac symptoms. [37] It is possible that
tissue specific changes in protein localization or protein-protein
association may contribute to the phenotype associated with this
specific mutation. Recent works suggests that functional ABCC6 at
the plasma membrane is coupled to the secretion of nucleotides
and the production of extracellular pyrophosphate. However,
nucleotide secretion is not mediated directly by ABCC6,
suggesting that plasma membrane ABCC6 function may be
coupled physically or functionally to the activities of other
transmembrane proteins. [60] This indirect regulation of secretory
activities could be accomplished by specific protein-protein
interactions mediated by the ABCC6 PDZ-like sequence at the
plasma membrane.
Taken together, our data suggest that the C-terminal PDZ-like
sequence is critical for the regulated trafficking and membrane
localization of ABCC6. Though this sequence varies from the
canonical PDZ-sequences found in other ABCC transporters, its
removal results in decreased protein expression and increased
degradation. These data provide evidence that the C-terminal
sequences in ABCC6 serve to regulate its biosynthetic processing
and membrane stability, thereby providing novel insight for the
regulation of ABCC6 in normal physiology and mechanisms for its
disruption in disease pathophysiology.
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